*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Jiangsu Recbio Technology Co., Ltd.**
**江蘇瑞科生物技術股份有限公司**
*(a joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 2179)**

# ANNOUNCEMENT ON COMPLETION OF INDUSTRIAL AND COMMERCIAL REGISTRATION AND RENEWAL OF BUSINESS LICENSE IN RESPECT OF CHANGES IN BUSINESS SCOPE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcements dated May 21, 2025 and June 20, 2025, respectively, and the notice and circular (the "**Circular**") of the annual general meeting both dated May 30, 2025 of Jiangsu Recbio Technology Co., Ltd. (the "**Company**") in relation to, among others, details of proposed changes in business scope and proposed amendments to the Articles of Association and related matters. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Company convened the AGM on June 20, 2025, at which it considered and approved (1) the Resolution on the Proposed Changes in Business Scope of the Company; and (2) the Resolution on the Proposed Amendments to the Articles of Association as referred to in the Circular (the "**Resolutions**"). The proposed changes in business scope will take effect on the date on which the market supervision and administration authority issues the new business license, and the amended Articles of Association will become effective from the date on which the proposed changes in business scope of the Company takes effect. The Company proceeded to apply to the market supervision and administration authority for alteration of registration and filing procedures upon passing of the Resolutions at the AGM. On August 8, 2025, the Company completed the industrial and commercial registration in respect of the changes in business scope and amendments to the Articles of Association, and obtained the business license renewed by the Taizhou Municipal Administration for Market Regulation.

In accordance with the requirements of the market supervision and administration authority on the standardized description of business scope, the description of business scope in the business license has been revised as follows:

| **Original business scope** | **Business scope considered and approved at the AGM** | **Revised business scope subject to approval of registration of the market supervision and administration authority** |
|---|---|---|
| Biotechnology research & development, technology transfer, technology consultation, self-operated and proxy import and export of commodities and technologies (except for commodities and technologies that are restricted by the state or prohibited from import and export). (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities) | Licensed projects: pharmaceutical production (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities, and the specific business projects are subject to the approval results)<br><br>General projects: bio-based materials technology research & development; bio-based materials manufacturing; bio-based materials sales; biotechnology research & development, technology transfer, technology consultation, self-operated and proxy import and export of commodities and technologies (except for commodities and technologies that are restricted by the state or prohibited from import and export). (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities) | Biotechnology research & development, technology transfer, technology consultation, self-operated and proxy import and export of commodities and technologies (except for commodities and technologies that are restricted by the state or prohibited from import and export). (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities)<br><br>Licensed projects: pharmaceutical production (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities, and the specific business projects are subject to the approval results)<br><br>General projects: bio-based materials technology research & development; bio-based materials manufacturing; bio-based materials sales (except for projects subject to approval in accordance with the laws, business activities shall be carried out independently based on the business license in accordance with the laws) |

In respect of the above revisions of the business scope, the Company made amendments to the Articles of Association accordingly based on the business scope approved by the market supervision and administration authority, which are detailed as follows:

| **Article Number** | **Before amendments** | **After amendments** |
|---|---|---|
| Article 13 | The business scope of the Company (to be finally determined by the local administration for market regulation) covers: biotechnology research & development, technology transfer, technology consultation, self-operated and proxy import and export of commodities and technologies (except for commodities and technologies that are restricted by the state or prohibited from import and export). (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities).<br><br>… | The business scope of the Company ~~(to be finally determined by the local administration for market regulation)~~ covers:<br><br>biotechnology research & development, technology transfer, technology consultation, self-operated and proxy import and export of commodities and technologies (except for commodities and technologies that are restricted by the state or prohibited from import and export). (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities).<br><br>**Licensed projects: pharmaceutical production (Business activities subject to approval in accordance with the laws can only be carried out after approval by relevant authorities, and the specific business projects are subject to the approval results).**<br><br>**General projects: bio-based materials technology research & development; bio-based materials manufacturing; bio-based materials sales (except for projects subject to approval in accordance with the laws, business activities shall be carried out independently based on the business license in accordance with the laws).**<br><br>… |

As mentioned in the Circular, the specific business scope is subject to the approval of registration of the market supervision and administration authority. As such, upon passing of the Resolutions at the AGM, the Company may make corresponding amendments based on the approval of registration of the market supervision and administration authority. The Board of the Company confirms that the amendments do not conflict with the Resolutions considered and approved by the Board and Shareholders at the AGM and do not require further approval at the next general meeting of the Company.

For the full text of the amended Articles of Association, please refer to the HKEXnews website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.recbio.cn).

By order of the Board
**Jiangsu Recbio Technology Co., Ltd.**
**Dr. LIU Yong**
*Chairman*

Jiangsu Province, the PRC, August 11, 2025

*As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.*